Bragar Eagel & Squire, P.C. is investigating potential claims against Replimune Group Inc. on behalf of Replimune stockholders. The investigation concerns whether Replimune violated federal securities laws or engaged in other unlawful business practices. The inquiry follows a July 28, 2026 FDA release of briefing documents stating that the single-arm mid-stage study for Replimune's skin cancer drug RP1 is not interpretable, which confounds interpretation of efficacy results and limits the FDA's ability to verify reported results. Replimune's stock price dropped $3.27, or 37.89%, in intraday trading that day. Stockholders who purchased or acquired Replimune shares and suffered a loss are encouraged to contact the firm.
Replimune Group IncFDA briefing documents question RP1 trial interpretability, causing 37.89% stock drop and securities law investigation.
